Investing Profile

Steven Gillis

InvestorVC

Managing Director at ARCH Venture Partners

Photo of Steven Gillis, Managing Director at ARCH Venture Partners

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
ARCH Venture Partners Managing Director
$50K - $150.0M
$25.0M
10
$635.8M
CompanyStageDateRound SizeTotal Raised
Mozart Therapeutics
Series AOct 2021$55M
$55M
Co-investors: Peter Dudek (MRL Ventures Fund)
HiberCell
Series BMay 2021$67.4M
Series AFeb 2019$60.8M
$128.2M
Co-investors: Ari Nowacek (ARCH Venture Partners)
Walden Biosciences
Series AOct 2020$51M
$51M
ImmusanT
Series CNov 2017$40M
$40M
EGenesis
Series AMar 2017$38M
$163M
Co-investors: Isaac Ciechanover (Polaris Partners), Srini Akkaraju (Samsara BioCapital), Boris Nikolic (Biomatics Capital Partners)
Carrick Therapeutics
Series AOct 2016$95M
$95M
Pulmatrix
Post-IPO EquityJun 2015$10M
$54.2M
Co-investors: Richard Ulevitch (5am Ventures), Scott Rocklage (5am Ventures), Kevin Bitterman (Atlas Venture), Dave Maki (Altitude Life Science Ventures (ALSV))
VentiRx Pharmaceuticals
Series BSep 2014$50.6M
$102.2M
Co-investors: Nicole Vitullo (Domain Associates)